Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | AKT1 | P31749 | 13/20 | 0.46 |
| ▸ | AKT2 | P31751 | 5/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2896812 | 0.90 | JAK2 (0.51) | JAK2AKT1AKT2KCNH2 | |
| SCHEMBL2893852 | 0.87 | JAK2 (0.55) | JAK2AKT1AKT2KCNH2 | |
| SCHEMBL2890607 | 0.86 | JAK2 (0.53) | JAK2AKT1AKT2KCNH2 | |
| SCHEMBL5528216 | 0.86 | JAK2 (0.54) | JAK2AKT1AKT2KCNH2 | |
| SCHEMBL2898847 | 0.86 | JAK2 (0.54) | JAK2AKT1AKT2KCNH2 | |
| SCHEMBL2897765 | 0.85 | JAK2 (0.52) | JAK2AKT1AKT2KCNH2 | |
| SCHEMBL2893767 | 0.85 | JAK2 (0.52) | JAK2AKT1AKT2KCNH2 | |
| SCHEMBL2890158 | 0.84 | CA1 (0.53) | JAK2AKT1AKT2KCNH2 | |
| SCHEMBL2890411 | 0.83 | JAK2 (0.50) | JAK2AKT1AKT2KCNH2 | |
| SCHEMBL2893892 | 0.83 | JAK2 (0.50) | JAK2AKT1AKT2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750151-B2 | Inhibitors of Akt activity | MERCK SHARP & DOHME CORP. (US) | 2010-07-06 | — | — | US | claimed |
| US-20080280899-A1 | Inhibitors of Akt Activity | MERCK SHARP & DOHME CORP. | 2008-11-13 | — | — | US | claimed |
| EP-1737861-A1 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2007-01-03 | — | — | EP | claimed |
| WO-2005100356-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2005-10-27 | — | — | WO | claimed |
| US-7750151-B2 | Inhibitors of Akt activity | MERCK SHARP & DOHME CORP. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20080280899-A1 | Inhibitors of Akt Activity | MERCK SHARP & DOHME CORP. | 2008-11-13 | — | — | US | disclosed |
| EP-1737861-A1 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005100356-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280899-A1 | Inhibitors of Akt Activity | AKT1, AKT2, AKT3 | JAK2 430/4885AKT1 1/4885AKT2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.